Indications for FETROJA:
Susceptible complicated urinary tract infections (cUTI), including pyelonephritis. Susceptible hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Give by IV infusion over 3hrs. Treat for 7–14 days. ≥18yrs (CrCl 60–119mL/min): 2g every 8hrs. (CrCl 30–59mL/min): 1.5g every 8hrs. (CrCl 15–29mL/min): 1g every 8hrs. ESRD (CrCl <15mL/min) with or without hemodialysis: 0.75g every 12hrs. (CrCl ≥120mL/min): 2g every 6hrs. On hemodialysis: initiate immediately after session. CCRT: see full labeling.
<18yrs: not established.
Increase in all-cause mortality (see full labeling); monitor. Reserve for use in those who have limited or no alternative treatment options. Penicillin or other beta-lactam allergy. Discontinue if an allergic reaction occurs. Seizure disorder. Other CNS reactions (eg, nonconvulsive status epilepticus, encephalopathy, coma). Renal impairment: monitor. Elderly: monitor renal function. Pregnancy. Nursing mothers.
May cause false (+) results in dipstick tests (urine protein, ketones, occult blood); use alternative methods to confirm (+) tests.
Diarrhea, infusion site reactions, constipation, rash, candidiasis, cough, elevations in liver tests, headache, hypokalemia, nausea, vomiting, hypomagnesemia, atrial fibrillation; C. difficile-associated diarrhea, hypersensitivity reactions.
Generic Drug Availability: